Tanja Lepir Mehdi Zaghouani Stéphane P Roche Ying-Ying Li Miguel Suarez Maria Jose Irias Niramol Savaraj
10.1097/MD.0000000000013804
Medicine (Baltimore)
2019 Jan;98(2):e13804.
CC BY
https://pubmed.ncbi.nlm.nih.gov/30633154/
Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Head and Neck Neoplasms / drug therapy Melanoma / drug therapy Nivolumab / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Head and Neck Neoplasms / drug therapy Melanoma / drug therapy Nivolumab / therapeutic use Case Reports Aged Combined Modality Therapy Disease Progression Drug Substitution Head and Neck Neoplasms / diagnostic imaging Head and Neck Neoplasms / pathology Humans Male Melanoma / diagnostic imaging Melanoma / pathology Retreatment Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological Nivolumab pembrolizumab
PMC6336603
30633154
Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report
2019